|
 China has not yet approved mixing doses of different vaccines using
different technologies, but the director of the Chinese Center for
Disease Control and Prevention said in April the country was
considering it as a way of boosting vaccine efficacy.
Five out of the seven vaccines used in China's inoculation campaign
are inactivated, meaning they use a coronavirus that cannot
replicate in human cells. These include the Sinovac shot and two
vaccines from Sinopharm.
CanSinoBIO's shot uses a modified common cold virus known as
adenovirus type-5 (Ad5) to carry genetic material from the
coronavirus protein into the body.
A total of 300 healthy adults aged 18-59 years will be recruited for
the trial.
Some participants who have received either one or two doses of
inactivated vaccine will receive a booster shot from CanSinoBIO. The
rest will be given the Sinovac vaccine as a booster for comparison.
[to top of second column] |
 The trial, which is currently
recruiting participants, is sponsored by disease
control authorities in the eastern province of
Jiangsu, according to the clinical trial
registration data on ClinicalTrials.gov, which
is maintained by a department under the National
Institute of Health of the United States.
The disease control authorities in Jiangsu are
also running a trial that mixes doses produced
by CanSinoBIO and a unit of Chongqing Zhifei
Biological Products.
(Reporting by Roxanne Liu and Ryan Woo. Editing
by Jane Merriman)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
